IMA
$5.63
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc...
Recent News
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
ImageneBio, Inc. ( NASDAQ:IMA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.